CSIMarket
 


Biocardia Inc  (BCDA)
Other Ticker:  
 
 

BCDA's Revenue Growth by Quarter and Year

Biocardia Inc's Revenue results by quarter and year




BCDA Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 0.11 0.08 0.05 0.21
III Quarter September 0.21 0.82 0.03 0.19
II Quarter June 0.97 0.07 0.03 0.09
I Quarter March 0.06 0.05 0.04 0.22
FY   1.35 1.02 0.15 0.71



BCDA Revenue fourth quarter 2022 Y/Y Growth Comment
Biocardia Inc reported Revenue improvement of 32.5% year on year in the fourth quarter 2022, to $ 0.11 millions, this is lower than Biocardia Inc's recent average Revenue rise of 57.37%.

Looking into fourth quarter 2022 results within Biotechnology & Pharmaceuticals industry 67 other companies have achieved higher Revenue growth. While Biocardia Inc' s Revenue rise of 32.5% ranks overall at the positon no. 1919 in the fourth quarter 2022.




BCDA Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December 32.5 % 60 % -76.19 % 110 %
III Quarter September -74.39 % 2633.33 % -84.21 % 137.5 %
II Quarter June 1285.71 % 133.33 % -66.67 % -62.5 %
I Quarter March 20 % 25 % -81.82 % 10 %
FY   31.96 % 580 % -78.87 % 14.52 %

Financial Statements
Biocardia Inc's fourth quarter 2022 Revenue $ 0.11 millions BCDA's Income Statement
Biocardia Inc's fourth quarter 2021 Revenue $ 0.08 millions Quarterly BCDA's Income Statement
New: More BCDA's historic Revenue Growth >>


BCDA Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December -49.52 % -90.24 % 66.67 % 10.53 %
III Quarter September -78.35 % 1071.43 % 0 % 111.11 %
II Quarter June 1516.67 % 40 % -25 % -59.09 %
I Quarter March -25 % 0 % -80.95 % 120 %
FY (Year on Year)   31.96 % 580 % -78.87 % 14.52 %




Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #68
Healthcare Sector #289
Overall #1919

Revenue Y/Y Growth Statistics
High Average Low
983.36 % 57.37 % -53.67 %
(Sep. 30, 2016)   (Dec 31 2020)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #68
Healthcare Sector #289
Overall #1919
Revenue Y/Y Growth Statistics
High Average Low
983.36 % 57.37 % -53.67 %
(Sep. 30, 2016)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Biocardia Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3773.24 % 138.75 % -100 %
(Sep 30 2016)  


BCDA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Biocardia Inc realized fall in Revenue from the third quarter by -49.52% to $ 0.11 millions, from $ 0.21 millions achived in the previous quarter.

As we analyse present shortcoming at the IV. Quarter, we should assume, that frequently IV. Quarter Revenue appear to be sluggish then in the quarter before, Hannah  Williams, a business advisor based in London said.

Within Biotechnology & Pharmaceuticals industry 131 other companies have achieved higher Revenue quarter on quarter growth. While Biocardia Inc's Revenue growth quarter on quarter, overall rank is 3644.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #132
Healthcare Sector #488
Overall #3644
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #132
Healthcare Sector #488
Overall #3644
Revenue Q/Q Growth Statistics
High Average Low
3773.24 % 138.75 % -100 %
(Sep 30 2016)  


BCDA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Biocardia Inc reported fall in Revenue from the third quarter by -49.52% to $ 0.11 millions, from $ 0.21 millions achived in the previous reporting period.

This is not big problem, as IV. Quarter Revenue generally gravitate to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 131 other companies have achieved higher Revenue quarter on quarter growth. While Biocardia Inc's Revenue growth quarter on quarter, overall rank is 3644.


Biocardia Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 1.35 $ 1.33 $ 1.93 $ 1.03 $ 1.02
Y / Y Revenue Growth (TTM) 33.2 % 34.93 % 891.79 % 572.55 % 600 %
Year on Year Revenue Growth Overall Ranking # 60 # 151 # 3161 # 3152 # 3404
Seqeuential Revenue Change (TTM) 2.04 % -31.49 % 87.95 % 1.38 % 3.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 1919 # 2607 # 311 # 1099 # 3550




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Biocardia Inc's cumulative twelve months Revenue were $ 1 millions, company would post below average annual Revenue growth of 3.36% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Biocardia Inc's Revenue growth from the 0.21% growth in Sep 30 2022.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 60, from total ranking in previous quarter at 151.

Revenue TTM Q/Q Growth Statistics
High Average Low
983.36 %
57.37 %
-53.67 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 68
Healthcare Sector # 11
Overall # 60

Revenue TTM Y/Y Growth Statistics
High Average Low
1061.96 %
108.16 %
-79.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 68
Sector # 289
S&P 500 # 1919
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Biocardia Inc's cumulative twelve months Revenue were $ 1 millions, company would post below average annual Revenue growth of -79.58% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Biocardia Inc's Revenue growth from the 0.21% growth in Sep 30 2022.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 60, from total ranking in previous quarter at 151.

Revenue TTM Q/Q Growth Statistics
High Average Low
983.36 %
57.37 %
-53.67 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 68
Healthcare Sector # 11
Overall # 60

Revenue TTM Y/Y Growth Statistics
High Average Low
1061.96 %
108.16 %
-79.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 68
Sector # 289
S&P 500 # 1919




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BCDA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for BCDA's Competitors
Revenue Growth for Biocardia Inc's Suppliers
Revenue Growth for BCDA's Customers

You may also want to know
BCDA's Annual Growth Rates BCDA's Profitability Ratios BCDA's Asset Turnover Ratio BCDA's Dividend Growth
BCDA's Roe BCDA's Valuation Ratios BCDA's Financial Strength Ratios BCDA's Dividend Payout Ratio
BCDA's Roa BCDA's Inventory Turnover Ratio BCDA's Growth Rates BCDA's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Jaguar Health inc 56.81%$ 56.806 millions
Collegium Pharmaceutical Inc 55.81%$ 55.807 millions
Morphosys Ag54.93%$ 54.927 millions
Xeris Biopharma Holdings Inc 54.67%$ 54.669 millions
Seelos Therapeutics inc 53.85%$ 53.846 millions
Assertio Holdings inc 51.07%$ 51.074 millions
Precision Optics Corporation Inc 51.06%$ 51.062 millions
Seer Inc 50.20%$ 50.196 millions
Deciphera Pharmaceuticals Inc 50.19%$ 50.192 millions
Guardion Health Sciences Inc 49.81%$ 49.809 millions
Aravive Inc 49.64%$ 49.645 millions
Avidity Biosciences Inc 49.51%$ 49.514 millions
Agilon Health Inc 49.02%$ 49.016 millions
Olink Holding Ab publ 47.25%$ 47.250 millions
Immunogen inc 47.07%$ 47.067 millions
Oak Street Health Inc 46.59%$ 46.587 millions
Envista Holdings Corporation46.10%$ 46.098 millions
Inotiv Inc 45.77%$ 45.770 millions
Adaptive Biotechnologies Corporation45.53%$ 45.526 millions
Heron Therapeutics Inc 45.38%$ 45.379 millions
Halozyme Therapeutics Inc 44.38%$ 44.378 millions
Eagle Pharmaceuticals inc 43.43%$ 43.429 millions
Alphatec Holdings Inc 43.24%$ 43.241 millions
Nuwellis Inc 42.45%$ 42.448 millions
Silk Road Medical Inc 41.77%$ 41.765 millions
Zai Lab Limited41.72%$ 41.722 millions
Sientra Inc 41.44%$ 41.435 millions
Icon Plc41.24%$ 41.245 millions
Atrion Corporation41.21%$ 41.207 millions
Silence Therapeutics Plc40.97%$ 40.967 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com